SLXN on Nasdaq

Silexion Therapeutics Corp

We are a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerSLXN on Nasdaq2
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersGeorge Town, Cayman Islands2
  • Incorporated inCayman Islands3
  • Business address12 Abba Hillel Road, Ramat Gan, L3 52506063
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI254900063EP9AZODNJ852
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressC/O Conyers Trust Company (Cayman) Limited, KY1-1111 George Town, Cayman Islands2
  • Registered withGeneral Registry, MC-4085262

See how the biggest companies compare on our leaderboards

We are a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (“ KRAS ”). The KRAS gene, when mutated, plays a central role in many cancer types, such as pancreatic, colorectal and lung, and is therefore considered to be an oncogene. This oncogene instructs cells to make the corresponding KRAS protein which has a controlling function in cell growth signaling in the cancer cells. While multiple pharmaceutical companies are pursuing strategies to inhibit or tag the KRAS protein for degradation and thereby limit its downstream signaling, our approach is differentiated by targeting the root cause of oncogenic signaling— we silence the KRAS oncogene itself, preventing the production of the oncogenic protein.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income56-$11.6M in 2025+148% since 2023
-$15.0M-$10.0M-$5.0M02023: -$4.7M-$4.7M20232024: -$12.6M-$12.6M2024+169%2025: -$11.6M-$11.6M2025−7%
Net income56-$11.9M in 2025+133% since 2023
-$20.0M-$15.0M-$10.0M-$5.0M02023: -$5.1M-$5.1M20232024: -$16.5M-$16.5M2024+223%2025: -$11.9M-$11.9M2025−28%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Research and development (including $0 and $1,796 from related party, for the year ended December 31, 2025 and December 31, 2024, respectively)$7.1M$5.8M
General and administrative (including $134 and $2,972 from related party, for the years ended December 31, 2025 and December 31, 2024, respectively)$4.5M$6.8M
TOTAL OPERATING EXPENSES$11.6M$12.6M
OPERATING LOSS$11.6M$12.6M
Financial expenses (income), net (including $232 and $(1,249) from related party, for the years ended December 31, 2025 and December 31, 2024, respectively)$277.0K$3.9M
LOSS BEFORE INCOME TAX$11.9M$16.5M
INCOME TAX$3.0K$10.0K
NET LOSS FOR THE YEAR$11.9M$16.5M
Equity holders of the Company$11.9M$16.4M
Non-controlling interests$0$76.0K
LOSS PER ORDINARY SHARE, BASIC$8.96$394.94
LOSS PER ORDINARY SHARE, DILUTED$8.96$394.94
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE1.3M shares41.6K shares
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE1.3M shares41.6K shares

Compare Silexion Therapeutics Corp with another company

Leadership

Who has led Silexion Therapeutics Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ilan Hadar2024–now

Chair

  1. Ilan Hadar2024–now

Chief financial officer

  1. Hadar Mirit Horenshtein2024–now
2025
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerMirit Horenshtein-Hadar named Aug 11, 202519

Former names

  • Biomotion SciencesMay 9, 2024 to Aug 15, 20243

Timeline

  1. Aug 15, 2024New chief executive Ilan Hadar becomes CEO9
  2. Apr 2, 2024Founded Silexion Therapeutics Corp is founded2

Filings

274 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 82 major events, 29 insider forms, 22 large holders, 1 private raises, 130 other. The latest 20:

  1. Oct 5, 2026DEF 14A EDGAR
  2. Sep 30, 20268-K EDGAR
  3. Sep 29, 2026424B3 EDGAR
  4. Sep 29, 20268-K EDGAR
  5. Sep 28, 2026SCHEDULE 13D/A EDGAR
  6. Sep 28, 20268-K EDGAR
  7. Sep 25, 20268-K EDGAR
  8. Sep 25, 2026PRE 14A EDGAR
  9. Sep 25, 20268-K EDGAR
  10. Sep 16, 2026DEFA14A EDGAR
  11. Sep 9, 2026DEFA14A EDGAR
  12. Aug 24, 2026DEF 14A EDGAR
  13. Aug 21, 20268-K EDGAR
  14. Aug 19, 2026SCHEDULE 13D/A EDGAR
  15. Aug 18, 2026SCHEDULE 13G EDGAR
  16. Aug 14, 2026PRE 14A EDGAR
  17. Aug 14, 202610-Q EDGAR
  18. Aug 14, 20268-K EDGAR
  19. Aug 13, 2026SCHEDULE 13G/A EDGAR
  20. Aug 13, 20268-K EDGAR

The 274 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 26, 2026Shirvan MitchellCSO and CDOSale22,818$1.36$31.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 1, 2025Raised $3.6 million in a private offering of equity Form D: 11 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27